This class of controller medications should not be used alone to treat asthma as they are associated with an increased risk of asthma related deaths:

Rationale: A. Xanthine derivatives like theophylline have a narrow therapeutic index and require frequent serum monitoring to prevent toxicity, but they are not primarily associated with increased asthma-related mortality when used alone. While they provide mild bronchodilation and anti-inflammatory effects, they are generally considered third-line therapy. Their use is limited more by systemic side effects and drug interactions than by a black box warning for death. B. Inhaled corticosteroids are the foundational therapy for asthma because they directly address the underlying chronic airway inflammation. They are highly effective and are actually associated with a significant decrease in the risk of asthma-related hospitalizations and mortality. Scientific guidelines recommend them as the primary controller across almost all stages of asthma to maintain long-term stability and prevent airway remodeling. C. Long Acting Beta Agonists (LABA) must never be used as monotherapy for asthma because they do not treat the underlying inflammatory process. Research indicates that using a LABA alone can mask worsening inflammation while providing bronchodilation, potentially leading to sudden, life-threatening asthma exacerbations. This pharmacological phenomenon led to a black box warning stating they must only be used in fixed-dose combinations with an inhaled corticosteroid. D. Leukotriene modifiers are oral controller medications that inhibit the action or synthesis of leukotrienes, which are potent mediators of bronchoconstriction and inflammation. While they may be less effective than inhaled steroids for some patients, they are not associated with a heightened risk of asthma-related death when used as monotherapy. They are often used as alternative or add-on therapy, especially in patients with comorbid allergic rhinitis.